Bertholet et al., 2010 - Google Patents
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosisBertholet et al., 2010
View HTML- Document ID
- 4905292459447396665
- Author
- Bertholet S
- Ireton G
- Ordway D
- Windish H
- Pine S
- Kahn M
- Phan T
- Orme I
- Vedvick T
- Baldwin S
- Coler R
- Reed S
- Publication year
- Publication venue
- Science translational medicine
External Links
Snippet
Despite the widespread use of the childhood vaccine against tuberculosis (TB), Mycobacterium bovis bacillus Calmette-Guérin (BCG), the disease remains a serious global health problem. A successful vaccine against TB that replaces or boosts BCG would include …
- 229960005486 vaccines 0 title abstract description 97
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bertholet et al. | A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis | |
| Lewinsohn et al. | Polyfunctional CD4+ T cells as targets for tuberculosis vaccination | |
| Nieuwenhuizen et al. | The recombinant Bacille Calmette–Guérin vaccine VPM1002: ready for clinical efficacy testing | |
| Andersen et al. | Tuberculosis vaccines–rethinking the current paradigm | |
| Feng et al. | Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis | |
| Ahsan | Recent advances in the development of vaccines for tuberculosis | |
| Kowalewicz-Kulbat et al. | BCG and protection against inflammatory and auto-immune diseases | |
| Olsen et al. | Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6 | |
| Skeiky et al. | Advances in tuberculosis vaccine strategies | |
| Aguilar-Be et al. | Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis | |
| Tiwari et al. | Infect and inject: how Mycobacterium tuberculosis exploits its major virulence-associated type VII secretion system, ESX-1 | |
| Gicheru et al. | Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection | |
| Kupz et al. | ESAT-6–dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo | |
| Flach et al. | Proinflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase | |
| Ferraz et al. | A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice | |
| Dalmia et al. | Prime–boost approaches to tuberculosis vaccine development | |
| Leroux-Roels et al. | Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02A candidate tuberculosis vaccine in purified protein derivative-negative adults | |
| Costa et al. | A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis | |
| Araújo et al. | CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2 | |
| Tsenova et al. | Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis | |
| Li et al. | Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice | |
| Bivona et al. | Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine | |
| Ly et al. | Tuberculosis: vaccines in the pipeline | |
| Cho et al. | A review of the BCG vaccine and other approaches toward tuberculosis eradication | |
| Dhanasooraj et al. | Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles |